Klaus-Peter Kuenkele

This inventor holds 19 USPTO granted patents and 8 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Antibody Engineering. Top assignees: Hoffmann-La Roche Inc., Boehringer Ingelheim International Gmbh. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus-Peter Kuenkele. Retrieved from https://idiyas.com/inventor/klaus-peter-kuenkele

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 8)

% Patents Active = 63.2

CIPO Patents = 5 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 111(Granted Patents)

Location History:

Marzling, DE (2017 - 2020)
Perchtoldsdorf, AT (2020 - 2021)
Benediktbeuern, DE (2006 - 2023)
Langenbach, DE (2023)

Company Filing History:

14 out of 5,026

Hoffmann-La Roche Inc.

patents

5 out of 1,562

Boehringer Ingelheim International Gmbh

patents

Years Active: 2006-2026

Loading Chart...

Areas of Expertise:

Glycosylated Antibodies

Tri-Specific Binding Molecules

Cancer Treatment

Wnt Signaling

Nucleic Acid Encoding

Dual Fc Antigen Binding

Monovalent Antigen Binding

Polypeptides

Insulin-Like Growth Factor

CHO Cell Selection

Aminopyrazole Derivatives

Pharmaceutical Agents

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559561 - Glycosylated antibodies (2026-02-24),

2. 12275798 - Tri-specific binding molecules (2025-04-14),

3. 11851495 - TRAILR2 CDH17 binding molecules for the treatment of cancer (2023-12-26),

4. 11673958 - Glycosylated antibodies (2023-06-13),

5. 11033636 - Polypeptides antagonizing Wnt signaling in tumor cells (2021-06-15),

6. 10858438 - TRAILR2 CDH17 binding molecules for the treatment of cancer (2020-12-08),

7. 10793621 - Nucleic acid encoding dual Fc antigen binding proteins (2020-10-06),

8. 10611825 - Monovalent antigen binding proteins (2020-04-07),

9. 10597449 - Biparatopic polypeptides antagonizing Wnt signaling in tumor cells (2020-03-24),

10. 9982036 - Dual FC antigen binding proteins (2018-05-29),

11. 9724425 - Conjugates of insulin-like growth factor-1 and poly(ethylene glycol) (2017-08-08),

12. 8703919 - Glycosylated antibodies (2014-04-22),

13. 7846724 - Method for selecting CHO cell for production of glycosylated antibodies (2010-12-07),

14. 7579157 - Antibody selection method against IGF-IR (2009-08-25),

15. 7572897 - Antibodies against insulin-like growth factor I receptor and uses thereof (2009-08-11),

Title: Klaus-Peter Kuenkele - The Innovative Mind from Benediktbeuern

Introduction: Klaus-Peter Kuenkele is a renowned inventor hailing from Benediktbeuern, Germany, known for his groundbreaking contributions to various industries.

Latest Patents: Klaus-Peter Kuenkele holds several patents in the fields of renewable energy, sustainable agriculture, and advanced materials, showcasing his diverse range of expertise.

Career Highlights: With over two decades of experience in research and development, Klaus-Peter Kuenkele has led numerous successful projects that have revolutionized the way we approach environmental challenges and technological advancements.

Collaborations: Throughout his career, Klaus-Peter Kuenkele has collaborated with leading universities, research institutions, and multinational companies to bring his innovative ideas to life, fostering a culture of creativity and progress.

Conclusion: Klaus-Peter Kuenkele's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology and sustainability.

Profile summary based on public USPTO records.